Treatment of BK virus with a stepwise immunosuppression reduction and intravenous immunoglobulin in pediatric kidney transplant. (5th February 2022)

• Record Type: Journal Article
• Authors: Mohammad, Dunya; Kim, Dean Y.; Baracco, Rossana; Kapur, Gaurav; Jain, Amrish
• Is Part Of: Pediatric transplantation. Volume 26:Number 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-05
• Subjects: BK virus and IVIG -- immunosuppression -- kidney transplant -- pediatric; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.14241
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: Background: BKV and BKVN are common in pediatric kidney transplant, but there is limited data on treatment approaches. Our objective was to study the prevalence of BKV and BKVN utilizing only plasma qPCR and report treatment outcomes with stepwise IR and IVIG. Methods: A retrospective study of all pediatric kidney transplants from 2013 to 2020. Excluded patients >21 years at transplant and immediate graft failure. Surveillance was conducted using only plasma BK qPCR at 1, 3, 6, 9, 12, 18, and 24 months and annually. BKV defined as ≥250 copies/ml and resolution as <250 copies/ml. Presumed BKVN as >10 000 copies/ml despite IR; and BKVN if confirmed on histology. Results: Fifty‐six patients were included in the study; 20 (35.7%) had BKV. BKV was associated with longer duration of stent, 40 vs. 33.5 days ( p = .004). Two patients (3.5%) had confirmed, and 2(3.5%) had presumed BKVN. The first‐line treatment was IR in 100% of patients. BKVN confirmed and presumed received IVIG every month for six doses. Viral resolution was achieved in 70%, and no difference was noted in estimated glomerular filtration rate between BKV and non‐BKV group ( p = .438). There were no rejection episodes, and graft survival was 100% over median follow‐up of 3 years. Conclusions: Plasma qPCR alone is adequate for screening and monitoring treatment of BKV and BKVN. A stepwise IR and IVIG resulted in BKV resolution in the majority of patients. Larger studies are required to study the role of IVIG in the treatment of BKVN.